|
Key
Features: |
|
| Title and year of the Document | The standardization system in the Russian federation health care system. Clinico-economic studies, 2002 |
| Affiliation of authors | Approved by the RF Ministry of Health |
| Main policy objective | Regulatory basis for patient management protocols and formulary lists and schedules. |
| Standard reporting format included | Yes, with specified steps of clinico-economic analysis |
| Disclosure | No, but follow Helsinki Declaration, standards and rules of Good Clinical Practice |
| Target audience of funding/ author’s interests | Those who conduct the clinoco-economic studies and use of the results. |
| Perspective | Can be societal, federal health care system, institutional, patient’s and family, medical insurers |
| Indication | Yes |
| Target population | Yes |
| Subgroup analysis | Not stated |
| Choice of comparator | Most often used, most effective, least expensive, recommended by a standard, no-intervention |
| Time horizon | Not stated |
| Assumptions required | Not stated |
| Preferred analytical technique | Any one of CMA, CEA, CUA, CBA. Substantiate needed |
| Costs to be included | Account all costs as completely as possible. May include: Direct medical costs, direct nonmedical costs, indirect costs. |
| Source of costs | Medical services tariffs in MMI, tariffs of commercial medical services, averaged tariffs of 3-5 institutions, own calculations. Average drug price estimates. |
| Modeling | Yes, requires details |
| Systematic review of evidences | Yes |
| Preference for effectiveness over efficacy | Not specific |
| Preferred outcome measure | Changes in health indices, QALYs |
| Preferred method to derive utility | Not stated |
| Equity issues stated | Not stated |
| Discounting costs | Yes, 5% |
| Discounting outcomes | Not stated |
| Sensitivity analysis-parameters and range | Not specific |
| Sensitivity analysis-methods | Not specific |
| Presenting results | Detailed description of the methodology and data processing. |
| Incremental analysis | Yes |
| Total C/E | Not stated |
| Portability of results (Generalizability) | Not specific. Efficacy from investigator’s own study or from literatures |
| Financial impact analysis | No |
| Mandatory or recommended or voluntary | |
